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ABSTRACT
Background: Glioblastoma (GBM) has a high rate of local recurrence despite
chemoradiotherapy (CRT). Genome-wide expression profiling was performed on
patient tumors before and after chemoradiotherapy to identify genes and gene
pathways associated with recurrence.
Results: Median time to recurrence was 8.9 months with median time to second
surgery of 9.6 months. The microRNA (miRNA) analysis identified 9 oncologic and
immune-related miRNAs to be differentially expressed, including the hypoxia-related
miR-210 and the immune-modulatory miR-146b. More than 1200 differentiallyexpressed genes were identified with RNA-sequencing (RNA-seq). Gene set
enrichment analysis (GSEA) identified p53 signaling, Notch, Wnt, VEGF, and MEK
gene sets enriched in recurrent GBM. Consistent with the miRNA profiling data, the
miR-146b target gene set from GSEA analysis was also associated with recurrence.
Methods: Fourteen patients with GBM recurrence after CRT who had available
tumor tissue from the initial diagnosis as well as recurrence were selected. Total
RNA was isolated from formalin-fixed paraffin-embedded (FFPE) tumor specimens.
Genome-wide expression profiling using RT-PCR for miRNA analysis and RNA-seq for
messenger RNA (mRNA) analysis were conducted to identify differentially-expressed
genes. GSEA was performed on the differential expression data.
Conclusions: Genome-wide expression profiling identifies multiple oncologic and
immune-related gene sets associated with GBM recurrence. In particular, immunerelated miR-146b is upregulated in recurrence and deserves further investigation.

INTRODUCTION

despite multi-modality therapy with median progressionfree survival (PFS) of 6.9 months and overall survival
(OS) of 14.6 months [2]. Outcomes have improved in
recent clinical trials with median OS of approximately 17
months [3, 4]. Tumor recurrence occurs predominantly
inside the radiation field rather than distantly [5],
suggesting a subpopulation of GBM cells that are highly
resistant to chemoradiotherapy (CRT). With recurrence,
treatment is more limited and outcomes remain poor

Glioblastoma (GBM, World Health Organizaiton/
WHO grade IV) is the most common malignant primary
brain tumor in adults and has an annual incidence of 3.2
in 100,000 in the United States [1]. Based on a large
randomized study, adjuvant radiation therapy (RT) and
temozolamide (TMZ) after maximal safe resection is the
standard of care for GBM, but the outcomes remain dismal
www.oncotarget.com
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[6]. Recent advances in immunotherapy have generated
excitement in developing novel approaches to treat this
devastating disease [7, 8]. For example, programmeddeath-1 (PD-1), an immune checkpoint surface receptor
expressed on lymphocytes, has been implicated as a
mediator of immune suppression by tumors such as
GBM [8]. Nivolumab, an anti-PD-1 checkpoint inhibitor,
is currently under investigation in two randomized
studies for newly diagnosed GBM (NCT02617589 and
NCT02667587). However, chemoradiotherapy for GBM
can result in severe and prolonged lymphopenia that
may contribute to tumor recurrence and interfere with
future success of immunotherapy [9, 10]. Thus, there is a
clear need to better understand the mechanisms of GBM
resistance to CRT and its interaction with immune system,
which will be crucial for the discovery of novel therapies
for this devastating disease. However, due to the difficulty
of access to GBM tissue, particularly recurrent tumor
tissue, detailed molecular profiling to compare changes in
tumors before and after CRT have been limited.
MicroRNAs (miRNAs) are a family of small noncoding RNA molecules (~22 nucleotides) that regulate
expression of thousands of protein-coding genes [11].
With the ability to regulate the expression of a large
number of genes, miRNAs function as master regulators
of important processes such as cell growth, apoptosis,
cancer initiation and progression [12, 13]. Functional
studies with modulation of certain miRNAs have
demonstrated direct effects on glioma stem cell properties
and sensitivity to CRT [14–17]. There is also increasing
evidence that miRNAs play important regulatory roles
on the immune pathways currently targeted by the major
immunotherapeutic approaches, including immune
checkpoint blockade, adoptive cell transfer, cancer
vaccines, and cytokine therapy [18].
Given the importance of miRNAs, we hypothesized
that miRNA expression changes in GBM after CRT may
allow an improved understanding of pathways responsible
for treatment resistance. We also employed a genome-wide
expression profiling approach of 14 GBM tumors before
CRT and their corresponding recurrent tumor after CRT to
identify oncologic and immune-related changes within the
recurrent tumors after CRT.

patient received concurrent bevacizumab. After recurrence
but before the second salvage surgery, three patients
received salvage bevacizumab-based chemotherapy, and
one patient received laser interstitial thermal therapy
(LITT). Median time to progression was 8.9 months
(range: 2.9–24.4). Median time to second surgery was 10.3
months (3.4–32.9). Only one patient was alive at the time
of this analysis. Median OS was 23.1 months (12.3–72.0).
O6-methylguanine-DNA-methyltransferase
(MGMT)
methylation and isocitrate dehydrogenase (IDH) status
were largely not assessed in this patient cohort.

miRNA profiling identifies oncologic and
immune-related miRNAs
miRNA profiling was performed for the initial and
recurrent tumors for all 14 patients. A real-time reverse
transcriptase-polymerase chain reaction (RT-PCR)
based miRNA profiling experiment revealed 9 miRNAs
differentially expressed with statistical significance in
recurrent GBM (Table 1). The miRNA with the greatest
fold change was miR-210 (recurrence/initial ratio 1.91,
p = 0.003), which has established roles in cell survival,
particularly in hypoxic conditions [23]. miR-146b, which has
been shown to be a critical mediator of immune-regulatory
pathways [24, 25], was also upregulated (recurrence/initial
ratio 1.55, p = 0.02). Table 1 also shows several select
predicted targets of the miRNAs based on miRDB prediction
(http://mirdb.org) [26], which correspond to oncologic and
immune-related genes, including Notch2 [27], TGFBR1
[28], STAT3 [29], FGFRL1 [30], and NOVA1 [31].

RNA-seq analysis
Given the multiple oncologic and immune-related
miRNAs differentially expressed in recurrent GBM, a
large-scale genome-wide expression profiling study using
RNA-sequencing (RNA-seq) was employed to identify
genes and gene pathways associated with recurrence. Due
to limited RNA quality from two patients as well as the
initial tumor of a third patient, RNA-seq was employed
on 11 initial and 12 recurrent RNA samples. More than
1200 genes were identified that were differentially
expressed with statistical significance (p < 0.05)
(Supplementary Table 2). Selected genes related to ironmetabolism, oncologic pathways, and immune function
are shown in Table 2, including transferrin (TF), ferritin
(FTL), fibroblast growth factor 1 (FGF1), TNF receptorassociated factor 4 (TRAF4), and signal transducer and
activator of transcription 1 (STAT1).

RESULTS
Patients and outcomes
Fourteen patients were eligible for the analysis
(Supplementary Table 1). There were 7 females and 7
males included in this study. The mean age was 53 years.
Patients received RT with concurrent temozolomide
followed by adjuvant temozolomide from 2006-2012. The
median dose to the planning target volume was 60 Gy. Two
patients had placement of carmustine implants (Gliadel
wafer; Eisai Inc) at the time of initial surgery and one
www.oncotarget.com
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Given the significant number of genes differentially
expressed, gene set enrichment analysis (GSEA)
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Table 1: miRNA differentially expressed in recurrent high-grade glioma
Fold change

p-value

Select predicted targets (mirdb)

hsa-mir-210

1.91

0.003

IGF2, FGFRL1, AIFM3, CEND1

hsa-mir-191

1.44

0.005

TMOD2 (neuronal), MAPK9, CRCAM, CDK6, Notch2, DAPK1, TRAF3,
BDNF

hsa-mir-101

1.66

0.005

TGFBR1, GLTSCR1

hsa-mir-126

0.44

0.016

MACC1, MAP3K2, TNFAIP8L3, RASAL2, CCNT2, MAPK10, TRAF6

hsa-mir-96

0.33

0.018

MTSS1, SDC2, NEUROD4, MAP2K1, RAB35

hsa-mir-146b

1.55

0.024

ITPR2, RGS4, IL1A, NAV3, NOVA1, SRSF6

hsa-mir-25

0.72

0.024

CD69, JMY, RAB23, MYO1B, MAP2K4

hsa-mir-24

1.41

0.031

CALCR, AAK1, KSR2

hsa-mir-20a

0.69

0.034

MAP3K2, PDCD1LG2, AAK1, TNFRSF21, NEDD4L

miRNA

*

Fold change represents the mean expression value of recurrent glioma divided by initial tumor. P-value calculated using a
paired Student’s T-test.

Table 2: Select differentially-expressed genes in recurrent GBM
Upregulated in recurrence
Gene name
transferrin

Gene symbol

Relative expression

P-value

TF

5.34

0.0085

interferon-induced protein with tetratricopeptide repeats 2

IFIT2

3.54

0.0006

apoptosis-associated tyrosine kinase

AATK

3.38

0.0125

cyclin-dependent kinase 18

CDK18

3.30

0.0292

breast carcinoma amplified sequence 1

BCAS1

2.94

0.0221

microtubule-associated protein 7

MAP7

2.59

0.0101

fibroblast growth factor receptor 2

FGFR2

2.42

0.0400

ferritin, light polypeptide

FTL

2.35

0.0025

fibroblast growth factor 1

FGF1

2.22

0.0058

signal transducer and activator of transcription 1

STAT1

2.08

0.0019

lysosomal-associated membrane protein 2

LAMP2

1.78

0.0008

Gene symbol

Relative expression

P-value

neurocan

NCAN

0.26

0.0433

glutamate receptor, ionotropic, AMPA 2

GRIA2

0.45

0.0334

fatty acid binding protein 7, brain

FABP7

0.48

0.0236

ets variant 1

ETV1

0.49

0.0209

nestin

NES

0.52

0.0370

TRAF4

0.53

0.0334

MAGED4

0.54

0.0076

NOVA1

0.55

0.0330

Downregulated in recurrence
Gene name

TNF receptor-associated factor 4
melanoma antigen family D, 4
neuro-oncological ventral antigen 1
P-values calculated using a two-sided Student’s T-Test

www.oncotarget.com
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was employed to identify pathways associated with
recurrence. Using this statistical tool, recurrent GBM
was noted to be enriched in gene sets associated with
the MEK, KRAS, Notch, VEGF, and Wnt pathways,
among others (Supplementary Table 3). Additionally,
the gene sets associated with P53, iron metabolism,
and interferon signaling were associated with GBM
recurrence (Figure 1A–1D). Given the association
between GBM recurrence and immune-related genes and
gene sets, we explored the immunologic story further.
Multiple immune-related gene sets were associated
with recurrence (Figure 1C–1D and data not shown).
Using the Leading Edge analysis in the GSEA statistical
software package [22] (Figure 2A), an overlap region
corresponding to multiple immune-related genes present
in multiple enriched gene sets was identified (Figure 2B).
Multiple immune-regulatory interferon-related genes as
well as STAT1/2 (Signal Transducer and Activator of

Transcription) in particular, which plays a key role in
tumor progression [32–34] and immune-modulation [29,
35–37], were present in this overlap region.

miR-146b gene set identified in GBM recurrence
We previously demonstrated increased expression
levels of the immune-modulatory miRNA, miR-146b,
in tumor tissue isolated from recurrent GBM (Table 1).
Interestingly, GSEA analysis of all miRNA gene sets revealed
that the gene set corresponding to miR-146b targets was
found to be enriched in GBM recurrence (Figure 3). Multiple
immune-related targets of miR-146b have been identified by
miRDB prediction (http://mirdb.org). Supplementary Table
4 shows several miR-146b target immune-related genes with
decreased expression from the RNA-seq dataset comparing
gene expression between recurrent and initial tumors,
including Nova1, HNRNPD/AUF1A, and SNX22.

Figure 1: Gene Set Enrichment Analysis (GSEA) in recurrent glioma. GSEA of differential expression between recurrent and

initial high-grade glioma demonstrates that recurrent GBM is enriched in genes that participate in the p53 tumor suppressor pathway (A),
heme metabolism (B) and interferon signaling (C–D). ES–enrichment score, NES–normalized enrichment score, FDR–false discovery
ratio.
www.oncotarget.com
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miR-146b fold change associated with local
recurrence

after repeated biopsy of intracranial tumors, detailed
expression profiling studies of miRNA and transcriptome
(or RNA) of GBM tumors before and after CRT have been
limited in the literature. Park et al. previously performed
a miRNA analysis on 2 untreated GBM tumors and 2
recurrent GBM tumors after CRT (from two different
patients) where they identified 43 miRNAs with at least
two-fold changes in expression levels in both of the
recurrent tumors (miR-146b is not among them) [38].
However, given the recurrent and initial tumors were
not from the same patients and the extremely limited
sample size, it’s difficult to interpret this study’s findings.
Bo et al. [39] analyzed the publically available miRNA
profile data from 12 paired primary and recurrent GBM
samples using microarrays. They noted that miR-146b
was downregulated in the recurrent samples. However,
the treatments of these 12 patients before their recurrences
were not described, so there may be inherent differences
between the patient populations. Furthermore, the
discrepancy may be due to the differences in the miRNA
profiling techniques. The PCR-based platform in the
current study has shown greater detection specificity
(at single-base level) than the microarray platform, and
it is commonly used to validate microarray or RNAseq results. Other studies have conducted genome and
exome sequencing of larger cohorts of paired initial and
recurrent GBM tumors, but they did not specifically
analyze miRNA expression changes [40, 41]. These

The median fold change of miR-146b between
recurrent and initial tumors was 1.5 (range: 0.6–5.4).
Low miR-146b change (ratio < 1.5) was associated with
significantly improved freedom from salvage surgery (
FFSS) (Figure 4B, p = 0.01) and a trend toward improved
freedom from local recurrence (FFLR) (Figure 4A, p = 0.06).
However, the local control did not translate to significant
difference on OS (p = 0.45, Figure 4C). Cox regression
analysis (Supplementary Table 5) using miR-146b ratio as a
continuous variable showed an association with time to local
recurrence (hazard ratio [HR] 1.59, 95% confidence interval
[CI] 1.007–2.52, p = 0.047) as well as time to salvage surgery
(HR 1.68, 95% CI 1.06–2.69, p = 0.03), but not with time to
death (HR 1.32, 95% CI 0.86–2.04, p = 0.21).

DISCUSSION
This pilot study compared miRNA and mRNA
expression profiles of 14 pairs of GBM tumors before
CRT and after recurrence. It identified several candidate
oncologic and immune-related miRNAs and gene
sets differentially expressed in recurrent GBM. In
particular, the immune-modulatory miRNA miR-146b
was significantly increased at recurrence and may be a
promising target for future studies. Due to the difficulty

Figure 2: Immune-related genes associated with recurrent glioma. Genes differentially expressed in recurrent gliomas enriched

across multiple immunologic gene sets. Investigation of the top most enriched genes in the various immunologic gene sets from the GSEA
(A) results in the boxed overlap region (B).
www.oncotarget.com

29040

Oncotarget

investigations from Li et al. [42], Katakowski et al. [43],
Liu et al. [44] and Yang et al. [45], who all demonstrated
that overexpression of miR-146b in a GBM cell culture
system reduces migration/invasion and increases apoptosis
and radiosensitivity. These results need to be taken with
the necessary caveats of an in vitro culture system which

studies paint complex pictures of mutation alterations and
evolutionary trajectories of GBM tumors during CRT but
do not explore the potential of common miRNA pathways
in GBM resistance. The differentially higher expression
of miR-146b in recurrent GBM found in our analysis of
paired recurrent and initial GBM is in contradiction to

Figure 3: Immune-related gene set miR-146b associated with recurrent glioma. GSEA reveals gene set associated with
targets of miR-146b associated with recurrent glioma, linking miRNA profiling results with RNA-seq gene expression analysis. ES–
enrichment score, NES–normalized enrichment score, FDR–false discovery ratio.

Figure 4: Clinical outcomes stratified by miR-146b expression ratio. Kaplan-Meier estimates of clinical outcomes stratified by
high and low miR-146b ratios between recurrent vs initial tumors (A) freedom from local recurrence, (B) freedom from salvage surgery,
and (C) overall survival.
www.oncotarget.com
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inherently lacks the complexity of GBM recurrence in
vivo. Our hypothesis presented in this manuscript is that
miR-146b upregulation in recurrence plays a role in GBM
immune-suppression potentially at a later stage of the
tumor progression event, ultimately resulting in tumor
recurrence. This manuscript challenges the notion of miR146b functioning as solely a tumor suppressor. Based on
our investigation of human GBM recurrent tumor tissue in
relation to the paired initial tumor, the role of miR-146b in
tumorigenesis, tumor progression, and tumor maintenance
is likely more complex than has been previously reported
in the literature.
A vast number of potential targetable pathways in
GBM have been identified in preclinical studies, but few
have shown efficacy in the clinical setting. Complicating
clinical efficacy is the heterogeneity of these tumors
stemming from the complexity of their molecular makeup
[41, 46]. This complexity is highlighted in the results
presented in this study using a Gene Set Enrichment
Analysis (GSEA) with recurrent GBM enriched in MEK,
NOTCH, SRC, RAF, P53, VEGF, and WNT gene sets.
Studies have shown redundant activation of numerous
signaling pathways, which likely explains the futility of
single-drug therapies [47].
This study implicates the immune-modulatory
miRNA miR-146b as an important factor to drive
GBM recurrence after chemoradiotherapy. Multiple
studies have established an immune-modulatory role
for miR-146b, including suppression of IL-6 allowing
p16-dependent tumorigenesis in breast cancer [24], as
well as suppression of multiple other pro-inflammatory
cytokines and chemokines such as TNF-alpha, IL8, and IL-10 [25]. Park et al. implicated miR-146b
in dendritic cell survival and cytokine production
via targeting of TRAF6 and IRAK1 [48]. Lu et al.
also recently showed that miRNA-146b are highly
expressed in regulatory T cells (Tregs) and play a
vital role in their expansion, survival, and suppressor
function [49]. Since Tregs have been implicated as a
major contributor to the evasion of immunosurveillance
by GBM and are correlated with poor prognosis [50],
our finding may be a reflection of the miRNA changes
of the infiltrating immune cells within the tumor
microenvironment rather than the tumor cells. Our
gene expression results highlight several established
miR-146b immune-modulatory targets, including
HNRNPD/AUF1A and SNX22 (Supplementary Table
4). HNRNPD/AUF1A is a nuclear ribonucleoprotein
with roles in NF-kB signaling and interleukin
expression [51]. SNX22 has been shown through
its role in endocytosis to down-regulate CD4 [52].
As immunotherapy continues to develop for GBM,
an improved understanding of the role of miR-146b
may help to develop novel approaches to overcome
the high level of immune suppression by the GBM
microenvironment [53–55].
www.oncotarget.com

Since this study is a small pilot study of genomeexpression profiling, its findings need to be interpreted
with the following limitations. As this study is based on
a limited sample size and a highly selected population
of GBM patients who underwent salvage surgery for
recurrence after CRT, the finding should be considered
hypothesis-generating. The small sample size limits
the use of stringent FDR-controlling method. External
validation using a larger sample size, ideally using a multiinstitutional tumor bank, will be necessary to confirm
our finding. Recent data have also shown significant
regional and cellular heterogeneity within GBM [56, 57].
Therefore, the expression profiling of our samples may
only represent snap-shots of the complex composition of
the tumor cells and tumor-infiltrating immune cells, and
other methods such as single-cell RNA-seq to compare
tumor cells before and after treatment will be needed to
provide validation in the future. Furthermore, our study
does not prove causality that the expression change
of miR-146b represents the mechanism driving the
recurrence rather than passive treatment-induced changes.
Functional studies in vitro and in vivo will be needed to
further confirm the role of miR-146b in promoting GBM
recurrence.
In conclusion, this study presents multiple
deregulated miRNAs and gene pathways after CRT
and implicates the immune-modulatory miR-146b
as a potential factor in GBM recurrence. Additional
investigations are warranted to validate the association
of miR-146b with GBM recurrence and to understand its
mechanisms.

MATERIALS AND METHODS
Patient selection
Eligible patients with pathologically diagnosed
GBM were identified from our institutional review board
(IRB)–approved database. They were required to have
received standard fractionated RT and concurrent daily
TMZ at 75 mg/m2 after maximal safe resection. These
patients were also required to have sufficient pathologic
tissue from the initial surgery before CRT and the salvage
surgery at the time of recurrence after CRT. Additional
salvage chemotherapies were allowed prior to the salvage
surgery. This study was reviewed and granted approval by
the IRB.

RNA isolation from tumor specimens
Formalin-fixed paraffin-embedded (FFPE) tumor
blocks from the initial and salvage surgeries were
collected for pathological analysis. FFPE specimens were
stained with hematoxylin and eosin (H&E), reviewed
by a board-certified neuro-pathologist (CC) to confirm
diagnosis and to demarcate tumor regions. This was
29042
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initial tumor (n = 11). Utilizing GSEA software available
from the Broad Institute [22], gene sets with member
genes enriched in recurrent GBM were discovered.
Statistically significant gene sets were considered with
p-value < 0.05 and FDR (false discovery ratio) < 0.25.
ES (enrichment score) reflects the degree to which a gene
set is over-represented in our dataset of differentially
expressed genes. NES (normalized enrichment score) is
the ES normalized for gene set size.

followed by macrodissection of 10-micron unstained
sections in order to remove non-tumor tissues. Total
RNA was then extracted using the miRNeasy FFPE Kit
(Qiagen) according to the manufacturer’s protocol.

miRNA profiling
miRNA expression profiling of 96 miRNAs
implicated in tumorigenesis was performed using our
laboratory’s previously described method, which is based
on RT-PCR, the details of which have been described
previously [19]. The RT reaction was performed with
the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA). Each RT reaction
included 150 ng of tumor RNA and miRNA-specific RT
primers. RT-PCR was performed with Power SYBR
Green PCR Master Mix (Applied Biosystems) and
miRNA-specific PCR primers. Raw profiling data based
on PCR threshold cycles (Ct) were normalized using a
quantile-based scaling method, which has been described
previously [19].

Statistical analysis
All time points were determined from the date
of initial surgery. Statistical significance (p < 0.05) for
differential expression was calculated using the Student’s
T-test. Median value of the fold change in miR-146b
expression in recurrent vs initial tumors was used as
cutoff to identify high fold change (mir-146b ratio ≥ 1.5)
vs low fold change (mir-146b ratio < 1.5). Freedom from
local recurrence (FFLR), freedom from salvage surgery
(FFSS), and overall survival (OS) were evaluated using
the Kaplan-Meier method and compared using the logrank test. Cox regression analysis was utilized to evaluate
the association of miR-146b fold change with clinical
outcomes. Statistical analyses were performed with the
Statistical Package for Social Sciences, version 22 (IBM
SPSS Statistics, Chicago, IL, USA). Significance was
defined as a p value ≤ 0.05. All statistical tests were two
sided.

RNA-seq for gene expression profiling in
recurrent and initial GBM
RNA-seq was performed to allow identification
and quantification of expression of genes in a given
tumor sample by a single massively parallel sequencing
run [20]. Details of the experimental protocol has
been described previously [21]. Total RNA was used
to construct multiplexed cDNA libraries, which were
provided to the Genome Technology Access Center
(GTAC) at Washington University School of Medicine
for sequencing. Ribosomal RNA (rRNA) was removed
using the RiboMinus kit (Life Technologies) and custom
designed rRNA probes. rRNA-depleted total RNA was
used as template for RNA-seq library construction using
the NEBNext mRNA Library Prep kit (New England
BioLabs). Double-stranded cDNA was synthesized
from rRNA-depleted total RNA, end-repaired, dAtailed, and then ligated to standard Illumina adaptor
oligonucleotides. Adaptor-ligated cDNA libraries were
loaded into HiSeq 2000 (Illumina) for sequencing. Raw
RNA-seq data (in fastq format) were made available after
the sequencing runs, which were parsed to align each
sequence read to the original RNA sample. Sequencing
reads were modified to remove low quality reads and
clustered before mapping to the human transcriptomes.
Gene expression levels were normalized using a strategy
based on the length of the transcript as well as the
number of total read counts from each sample (reads per
kilobase per million, RPKM).
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